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BACKGROUND. A Phase II trial was conducted at the University of Michigan to
determine the efficacy of a preoperative regimen of concurrent cisplatin, paclitaxel,
and radiation for patients with locoregional esophageal carcinoma.
METHODS. Sixty-nine patients with esophageal carcinoma were treated with cis-
platin 75 mg/m2 on Day 1, paclitaxel 60 mg/m2 on Days 1, 8, 15, and 22, and
radiation 1.5 Gray (Gy) twice per day on Days 1–5, 8 –12, and 15–19, for a total dose
of 45 Gy. Transhiatal esophagectomy was performed on approximately Day 50.
RESULTS. The treatment regimen was well tolerated. Only 13% of patients devel-
oped Grade 3 or 4 neutropenia and 17% of patients required feeding tubes. Ninety
percent of all patients had complete tumor resection at the time of surgery.
Nineteen percent of patients achieved a complete histologic response in the
resected specimen. The median survival period was 24 months. One-, 2-, and
3-year survival probabilities were 75%, 50%, and 34%, respectively.
CONCLUSIONS. This cisplatin-based preoperative regimen, which contained pacli-
taxel rather than 5-fluorouracil, was well tolerated. The survival data compared
favorably with other previously reported combinations. This regimen is a reason-
able preoperative approach for patients with localized esophageal carcinoma.
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Patients with localized esophageal carcinoma are treated with sur-gery alone, primary chemoradiation, or chemoradiation followed
by surgery. Despite many randomized trials, there is no definitive
proof that any one approach is superior. At the University of Michigan
(Ann Arbor, MI), we have had an interest for many years in exploring
new chemoradiation combinations before surgery. Many chemora-
diation regimens have utilized cisplatin and 5-fluorouracil (5-FU), but
other agents such as paclitaxel and more recently irinotecan have
demonstrated activity in this disease.1 At the time we designed this
study, we decided to further evaluate the role of paclitaxel in a
chemoradiation regimen. Ajani et al.2 reported a Phase II trial in
which 46 patients with esophageal carcinoma were treated every 21
days with paclitaxel 250 mg/m2 and granulocyte– colony-stimulating
factor (G-CSF). The partial response rate in their study was 31%. Choy
et al.3 conducted a Phase I trial of concurrent weekly paclitaxel and
radiotherapy for patients with nonsmall cell lung carcinoma. Al-
though the trial was not designed for patients with esophageal carci-
noma, the radiation fields in patients with lung carcinoma and esoph-
ageal carcinoma often include similar anatomic structures. Therefore,
the toxicity data were considered relevant to esophageal carcinoma.
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When administered along with 60 Gray (Gy) of radia-
tion, paclitaxel 60 mg/m2 per week was the maximum
tolerated dose in that study and esophagitis was the
most common dose-limiting toxicity. We designed a
trial to combine cisplatin and paclitaxel administered
concurrently with radiotherapy, before transhiatial
esophagectomy, to determine the efficacy of this com-
bination.
MATERIALS AND METHODS
Eligibility criteria included the following: 1) new diag-
nosis of histologically confirmed squamous cell carci-
noma, adenocarcinoma, or undifferentiatied carci-
noma of the esophagus or gastroesophageal junction;
2) no previous treatment; 3) disease limited to the
esophagus or regional lymph nodes and able to be
encompassed in a single radiation field; 4) no medical
contraindication to surgery; 5) a Karnofsky perfor-
mance status greater than 60%; 6) age younger than 75
years; 7) creatinine clearance greater than 60 mL/min;
8) a white blood cell count greater than 3500 cells per
microliter and a platelet count greater than100,000
cells per microliter; 9) no previous malignancy or pre-
vious malignancy only if the patient was considered to
be cured; 10) no serious medical conditions that
would preclude safe administration of treatment; and
11) ability to give informed consent.
Staging
Patients were staged with upper endoscopy and bi-
opsy, barium swallow, and a computed tomograpy
(CT) scan of the chest and abdomen. The rare patient
with involvement of celiac lymph nodes was not ex-
cluded. During this period of time at the University of
Michigan, we were not routinely using endoscopic
ultrasound or laparoscopy for preoperative evalua-
tion.
Chemotherapy
Paclitaxel 60 mg/m2 was administered on Days 1, 8,
15, and 22. The drug was diluted in at least 500 mL of
5% dextrose solution or 0.9% sodium chloride solution
and infused over 3 hours. All patients were premedi-
cated with dexamethasone 20 mg orally 12 and 6
hours before paclitaxel administration and with di-
phenhydramine 50 mg intravenously (i.v.) and cime-
tidine 300 mg i.v. 30 minutes before they received
paclitaxel. Vital signs were monitored closely during
the infusion.
Cisplatin 75 mg/m2 was given on Day 1 as a
2-hour infusion. Patients were prehydrated with 1 L of
5% dextrose in 0.9% sodium chloride solution. A 12.5 g
mannitol i.v. bolus was given immediately before cis-
platin, after which 25 g mannitol in 1000 mL of D5-
normal saline was infused over 4 hours during and
after the cisplatin infusion. Fluid intake and output
were measured carefully and additional fluids were
given i.v. to match excessive loss from emesis, diar-
rhea, or urine.
G-CSF was administered in a dose of 5 g/kg per
day subcutaneously, starting 24 hours after the cessa-
tion of the fourth dose of paclitaxel and continuing
until the absolute neutrophil count was greater than
10,000 cells per microliter.
Radiotherapy
All patients were positioned supine in a customized
low-density foam cradle and underwent a treatment
planning CT scan in the same position. Within our
three-dimensional conformal treatment planning sys-
tem, a gross tumor volume (GTV) was identified based
on abnormalities observed in the esophagus, proximal
stomach, and regional lymph nodes on a pretreatment
diagnostic CT scan and barium swallow and at the
time of esophagus copy (EGD). A planning target vol-
ume (PTV) then was identified by expanding the GTV
5 cm superiorly and inferiorly and 1.5 cm radially.
Steps were taken to ensure that all enlarged lymph
nodes were adequately covered by the PTV. Unin-
volved lymph node regions were not purposefully in-
cluded. The goals of treatment planning were to en-
compass the PTV with the 95% isodose surface and to
minimize the dose to the surrounding normal struc-
tures. The dose to the spinal cord was limited to 36 Gy
in all cases. A four-field conformal beam arrangement
consisting of opposed anterior and posterior and lat-
eral fields typically was used. A dose of 1.5 Gy was
delivered twice daily on Days 1–5, 8 –12, and 15–19
with a minimum interfraction interval of 6 hours, re-
sulting in a total dose of 45 Gy.
Preoperative Assessment
Patients underwent a repeat CT scan of the chest and
abdomen and barium swallow approximately 1 week
before the planned esophagectomy to rule out devel-
opment of metastatic disease that would preclude sur-
gery.
Surgery
Transhiatal esophagectomy was performed on ap-
proximately Day 50. Through an upper midline ab-
dominal incision and a cervical incision, the entire
thoracic esophagus was mobilized and resected from
the level of the clavicles to the gastric cardia. The
remaining stomach was mobilized and positioned in
the posterior mediastinum in the original esophageal
bed. Alimentary continuity was reestablished by anas-
tomosis between the cervical esophagus and the gas-
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tric fundus, above the level of the clavicles. A gastric
drainage procedure, generally a pyloromyotomy, and
a feeding jejunostomy were performed routinely. In
patients with previous gastric surgery and an inade-
quate remaining length of stomach to reach to the
neck for a cervical esophageal anastomosis, the esoph-
agus was replaced with colon. Accessible intraabdomi-
nal, paraesophageal, and subcarinal lymph nodes
were sampled for the purpose of staging.
Statistical Design
The primary objective was to determine the rate of
complete histologic response induced by the preoper-
ative regimen of chemoradiation. A second objective
was to determine the overall survival and time to
disease recurrence in patients treated with this regi-
men.
In a former trial at the University of Michigan,
25% of patients treated with a fairly toxic preoperative
regimen of cisplatin, 5-FU, vinblastine, and radiation
achieved a complete response.3 Our goal was to dem-
onstrate that if the new regimen could be equivalent
in efficacy to the previous regimen, it could be con-
sidered superior because paclitaxel is generally less
toxic than 5-FU and vinblastine. We would consider
the paclitaxel preoperative regimen to be equivalent to
the vinblastine regimen if the 1-sided lower bound of
the 95% confidence interval (CI) for a histologic com-
plete response (CR) included 0.20. The 1-sided lower




Between January 1995 and September 1997, 69 pa-
tients were enrolled in the current study. Written in-
formed consent was obtained from all patients. Pa-
tient characteristics are summarized in Table 1. The
majority of patients were male and a preponderance
had adenocarcinoma.
Toxicity
Treatment was generally very well tolerated. One pa-
tient had an allergic reaction to paclitaxel during the
first few minutes of his first infusion, which consisted
of flushing, dyspnea, tachycardia, and chest tightness.
He recovered without sequelae and was treated with
two cycles of cisplatin and 5-FU concurrent with the
radiation. The remaining 68 patients received the full
dose of cisplatin as planned and 50 patients (72%)
received 100% of the planned dose of paclitaxel.
Twelve patients (17%) required feeding tube support.
There were no preordained criteria for feeding tube
placement, but decisions were based on the patient’s
ability to maintain adequate hydration and nutrition.
Grade 3/4 neutropenia was experienced by 9 patients
(13%). Three patients (4%) experienced febrile neutro-
penia. Two patients (3%) required a blood transfusion
for anemia.
Surgery Results
Sixty-eight patients underwent surgery. The one pa-
tient who did not undergo resection experienced total
esophageal obstruction during preoperative treat-
ment. During endoscopy to attempt dilatation and
laser treatment, a perforation of the esophagus oc-
curred. He subsequently underwent stent placement
and completed definitive radiation without surgery.
Sixty-one patients (90 %) had no macroscopic re-
sidual tumor, and 7 patients (10 %) had metastatic
disease. There was one intraoperative death. Thirteen
patients (19%) achieved a histologic CR.
Survival
All 69 patients were included in the survival analysis.
The survival probability estimates were obtained by
the Kaplan–Meier method. The median follow-up
time was 24 months for all patients and 47 months for
patients who still were alive. Forty-nine patients (71%)
died of disease or other causes. The median survival
time was 24 months (95% CI, 16 –33). The 1-, 2-, and
3-year survival probabilities were 75% (95% CI, 65–
86%), 50% (95% CI, 39 – 63%), and 34% (95% CI, 23–
46%), respectively. The Kaplan–Meier curve for overall
survival is shown in Figure 1.
The effects of some variables (age, histology, Bar-



















a Includes 20 cases of Barrett esophagus.
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sification, and N classification) on survival and the
corresponding risk ratios were determined based on
Cox proportional hazard models (Table 2). A margin-
ally significant effect was found only for histology (P
 0.05), in favor of squamous cell carcinoma (risk
ratio, 0.3) compared with adenocarcinoma. Not sur-
prisingly, the risk ratios indicate that a higher T clas-
sification and a higher N classification are associated
with an adverse effect on patient survival. Compared
with T0 tumors, the risk ratio for T1–T2 tumors was 2.1
and the risk ratio for T3–T4 tumors was 2.5. The risk
ratio for N1 disease was 1.7 compared with N0 disease.
Disease-free survival probability was investigated
using the Kaplan–Meier method and was measured
from the start of treatment until disease recurrence. Of
the 69 patients, 8 patients (12%) were never rendered
free of disease and therefore were considered to have
no disease-free time. This included one patient who
died during surgery and one patient who withdrew
from the study. Forty patients (58%) eventually had a
recurrence of disease. The median disease-free sur-
vival time was 14 months (95% CI, 9 –25). The 1-, 2-,
and 3-year disease-free survival probabilities were
55% (95% CI, 43– 67%), 39% (95% CI, 28 –51%), and
32% (95% CI, 21– 43%), respectively. The disease-free
survival curve is shown in Figure 2.
Landmark Analysis: Complete Responders Versus Non–
Complete Responders
Overall and disease-free survival times were compared
between complete responders (those with T0N0 at
surgery) and nonresponders. To avoid potential bi-
ases, landmark analysis was performed.4 The land-
mark time by which all patients’ responses were de-
termined was set at 3 months after the start of
treatment. Only patients with survival times longer
than 3 months were included in the current analysis.
FIGURE 1. Overall survival.
TABLE 2
Risk Ratios for Overall Survival
Variable No. RR 95% CI P value
Age
Younger than median 35 1.0 — — —
Older than median 34 1.0 0.6 1.8 0.91
Histology
Adenocarcinoma 57 1.0 — — —
Squamous cell carcinoma 10 0.3 0.1 1.0 0.05
Barrett esophagus
No 37 1.0 — — —
Yes 20 0.6 0.3 1.1 0.13
Lymphadenopathy on CT
No 36 1.0 — — —
Yes 33 1.4 0.8 2.5 0.22
T classification
T0 16 1.0 — — —
T1–T2 21 2.1 0.9 5.2 0.10
T3–T4 25 2.5 1.0 5.9 0.04
N classification
N0 28 1.0 — — —
N1 31 1.7 0.9 3.3 0.09
RR: risk ratio; CI: confidence interval; CT: computed tomography.
FIGURE 2. Disease-free survival.
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Survival probability estimates were obtained using the
Kaplan–Meier method.
Landmark Survival
Sixty-seven patients who were known to have survived
beyond the 3-month landmark time were included in
the current analysis. Of these 67 patients, 13 (22%)
were complete responders. Figure 3 shows the
Kaplan–Meier curves for complete responders and
nonresponders. The 1-, 2-, and 3-year survival proba-
bilities for the complete responders were 85% (95% CI,
65–100%), 85% (95% CI, 65–100%), and 69% (95% CI,
44 –94%), respectively. The 1-, 2-, and 3-year survival
probabilities for the nonresponders were 74% (95% CI,
62– 86%), 44% (95% CI, 31–58%), and 27% (95% CI,
15–39%), respectively.
Fifty-nine patients who had at least 3 months of
disease-free survival time were included in the current
analysis. Of these 59 patients, 13 (22%) were complete
responders. Figure 4 shows the Kaplan–Meier curves
for complete responders and nonresponders. The 1-,
2-, and 3-year disease-free survival probabilities for
the responders were 85% (95% CI, 65–100%), 77%
(95% CI, 54 –100%), and 69% (95% CI, 44 –94%), re-
spectively. The 1-, 2-, and 3-year survival probabilities
for the nonresponders were 59% (95% CI, 44 –73%),
37% (95% CI, 23–51%), and 28% (95% CI, 15– 41%),
respectively.
DISCUSSION
Patients treated with cisplatin, paclitaxel, and concur-
rent radiation in the current trial tolerated the regi-
men well. Only 13% of patients experienced Grade 3 or
4 neutropenia and 17% required feeding tubes. We
were disappointed that the histologic CR rate was only
19%. Yet, the median survival period was 24 months
and the 1- and 3-year survival rates were 75% and
34%, respectively. This compares favorably with other
trials of preoperative chemoradiation for esophageal
carcinoma. Urba et al.5 published a randomized trial
of preoperative chemoradiation versus surgery alone
performed at the University of Michigan. The chemo-
therapy regimen, which was substantially more inten-
sive, comprised a cisplatin total dose of 200 mg/m2,
5-FU, and vinblastine. The associated toxicity was
greater: the rate of Grade 3 or 4 granulocytopenia was
78%, and 63% of patients required feeding tubes.
However, in that study, the median survival period for
patients who received the multimodality treatment
arm was 17 months, which is poorer than the median
survival period achieved in the current study. The 1-
and 3-year survival rates for the multimodality arm in
the randomized trial were 72% and 30%, respectively,
which are extremely similar to the rates in the current
study. We have not become more selective in evalu-
ating patients for the trials. All patients in both trials
were staged in a similar fashion, and unless there was
evidence of metastatic disease or a true contraindica-
FIGURE 3. Overall survival for complete responders and non-complete
responders. Solid line: non-complete responders; dotted line: complete re-
sponders.
FIGURE 4. Disease-free survival for complete responders and non-complete
responders. Solid line: non-complete responders; dotted line: complete re-
sponders.
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tion to subjecting a patient to this type of therapy, all
patients were offered the protocol treatment.
Several other trials have been conducted to eval-
uate preoperative chemoradiation before surgery.
Walsh et al.6 reported on 58 patients with adenocar-
cinoma who were treated with cisplatin, 5-FU, and
radiation before surgery versus 55 patients treated
with surgery alone. The survival rates for the multi-
modality group were 52% at 1 year and 32 % at 3 years.
The trial conducted by Walsh et al. is the only one that
has shown statisticial superiority for the chemoradia-
tion arm, but the surgical arm survival rate of 6% at 3
years is inferior to the results typically achieved with
surgery alone. Bossett et al.7 reported the results of a
randomized trial conducted by the European Organi-
zation for Research and Treatment of Cancer, in which
282 patients with Stage I and II squamous cell carci-
noma of the esophagus were treated with either pre-
operative cisplatin and radiation or surgery alone. The
multimodality group achieved a 1-year survival rate of
72% and a 3-year survival rate of 36%. Recently, Bur-
meister et al.8 reported the results of a large Australian
trial comparing surgery alone with preoperative cis-
platin, 5-FU, and radiation in 256 patients with esoph-
ageal carcinoma. The median survival was similar for
both arms. For the chemoradiation arm, the 1-year
survival rate was 75% and the 3-year survival rate was
35%. These rates are quite similar to the rates achieved
in the current trial.
Historically, most trials have shown evidence that
histologic complete responders have better survival
than patients with evidence of residual disease at time
of surgery. This also is true in the current study, as
reflected in Figure 3. Although 81% of patients had
residual tumor in their esophagus after the preopera-
tive treatment with chemoradiation, the 1- and 3-year
survival rates for this “poorer prognosis” group were
very good (i.e., 74% and 27%, respectively), resulting in
a reasonable survival rate for the whole group. We
believe that these results strongly support to the role
of surgery as part of the treatment regimen for these
patients. Surgery can eliminate the disease that per-
sists after chemoradiation, allowing 27% of patients in
the current study to be alive at the 3-year follow-up.
Paclitaxel was introduced recently to preoperative
regimens to determine whether this agent can in-
crease efficacy or whether it can serve as an appropri-
ate substitute for 5-FU, which has the fairly troubling
side effects of mucositis and diarrhea. Paclitaxel and
radiation have been combined because paclitaxel syn-
chronizes cells at G2/M, a relatively radiosensitive
phase of the cell cycle. In one Phase I study, the
maximum tolerated dose of paclitaxel was 50 mg/m2
per week for 6 weeks with once-daily radiation to a
total dose of 50 Gy.9 The dose-limiting toxicities were
pain within the radiation field, nausea, and anorexia.
In another trial, paclitaxel and cisplatin were
given concurrently with radiation to 41 patients with
esophageal carcinoma.10 The paclitaxel dose was 60
mg/m2, and the cisplatin dose was 25 mg/m2; both
were administered weekly for 4 weeks, with once-daily
radiation to a total dose of 39.6 Gy in 1.8 Gy fractions.
Only 5% of patients had Grade 4 esophagitis requiring
parenteral nutrition. Twenty-nine percent of patients
achieved a CR and a 2-year survival rate of 42%. The
2-year survival rate of 50% reported in the current
study compares favorably with that trial. Adelstein et
al.11 reported their experience with 2 cycles of cispla-
tin 20 mg/m2 per day for 4 days and paclitaxel 175
mg/m2 for 1 day concurrent with a split course of
accelerated radiation (1.5 Gy twice per day to a total
dose of 45 Gy with a 12-day break). Forty patients with
locally advanced esophageal carcinoma were treated,
and 93% had disease that was resectable for cure, with
a 3-year survival rate of 30%. There was no survival
advantage and more toxicity when compared with
historical control patients treated with a cisplatin and
5-FU– based combination. However, the radiation was
accelerated and the paclitaxel was delivered in
monthly high doses, rather than in weekly low doses.
Paclitaxel has also been added to the classic reg-
imen of cisplatin, 5-FU, and radiation for patients with
esophageal carcinoma. Investigators at The University
of Texas M. D. Anderson Cancer Center reported a
trial involving 2 courses of induction chemotherapy
with cisplatin, 5-FU, and paclitaxel before 45 Gy of
radiation in 1.8 Gy fractions that was delivered con-
currently with a course of cisplatin and 5-FU.12 The
regimen resulted in a 30% histologic CR. The median
follow-up was only 20 months, but the 1-year survival
rate was 81%.
Heath et al.13 conducted a Phase II trial of contin-
uous-infusion cisplatin and 5-FU with radiotherapy,
followed by esophagectomy and then three postoper-
ative cycles of cisplatin and paclitaxel. Forty-two pa-
tients were enrolled, 39 of whom proceeded to sur-
gery. They achieved a 26% pathologic CR rate. At a
median follow-up of 30.2 months, the median survival
time was not yet reached and the 2-year survival rate
was 62%.
The current trial supports the feasibility of incor-
porating paclitaxel into perioperative regimens for pa-
tients with esophageal carcinoma. The toxicity profile
is different from 5-FU and may be better tolerated in
some patients. However, because recurrent disease is
not uncommon after chemoradiation followed by sur-
gery, future directions include incorporating newer
agents into chemotherapy combinations and attempt-
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ing to control residual micrometastatic disease with
antiangiogenic agents or other unique targeted ther-
apy. The role of preoperative chemoradiation and sur-
gery may be maximal debulking of the tumor, followed
by long-term treatment with targeted therapy in-
tended to prevent the growth of microscopic disease.
Our future direction at the University of Michigan
includes preoperative chemoradiation followed by
chronic suppressive therapy with an antiangiogenic
agent.
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